1
. Blood pressure is determined by complex interactions between life-course exposures and genetic background [2] [3] [4] . Previous genetic association studies have identified and validated variants at 274 loci with modest effects on population blood pressure, explaining in aggregate ~ 3% of the trait variance [5] [6] [7] [8] [9] [10] [11] [12] .
Here we report genome-wide discovery analyses of blood pressure traits-systolic blood pressure (SBP), diastolic blood pressure (DBP) and pulse pressure (PP)-in people of European ancestry drawn from UK Biobank (UKB) 13 and the International Consortium of Blood Pressure Genome Wide Association Studies (ICBP) 11, 12 . We adopted a combination of a one-and two-stage study design to test common and low-frequency single nucleotide polymorphisms (SNPs) with minor allele frequency (MAF) ≥ 1% associated with blood pressure traits (Fig. 1) . In all, we studied over 1 million people of European descent, including replication data from the US Million Veteran Program (MVP, n = 220,520) 14 and the Estonian Genome Centre, University of Tartu (EGCUT, n = 28,742) Biobank 15 . UKB is a prospective cohort study of ~ 500,000 richly phenotyped individuals, including blood pressure measurements 13 , with genotyping by customized array and imputation from the Haplotype Reference Consortium (HRC) panel, yielding ~ 7 million SNPs (imputation quality score (INFO) ≥ 0.1 and MAF ≥ 1%) 16 . We performed genome-wide association studies (GWAS) of blood pressure traits (n = 458,577 Europeans) under an additive genetic model 17 (Supplementary Table 1a ). Following linkage disequilibrium (LD) score regression 18 , genomic control was applied to the UKB data before meta-analysis (Methods).
In addition, we performed GWAS analyses for blood pressure traits in newly extended ICBP GWAS data comprising 77 independent studies of up to 299,024 Europeans genotyped with various arrays and imputed to either the 1000 Genomes Reference Panel or the HRC platforms (Supplementary Table 1b) . After quality control, we applied genomic control at the individual study level and obtained summary effect sizes for ~ 7 million SNPs with INFO ≥ 0.3 and heterogeneity Cochran's Q statistic 19 filtered at P ≥ 1 × 10 −4 (Methods). We then combined the UKB and ICBP GWAS results using inversevariance-weighted fixed-effects meta-analysis (Methods), giving a total discovery sample of up to 757,601 individuals 20 . In our two-stage design, we attempted replication (in MVP and EGCUT; Supplementary Table 1c) of 1,062 SNPs at P < 1 × 10
from discovery with concordant effect direction between UKB and ICBP, using the sentinel SNP (that is, the SNP with smallest P-value at the locus) after excluding the HLA region (chr. 6: 25-34 MB) and all SNPs in LD (r 2 ≥ 0.1) or ± 500 kb from any previously validated blood pressure-associated SNPs at the 274 published loci. Our replication criteria were genome-wide significance (P < 5 × 10 −8 ) in the combined meta-analysis, P < 0.01 in the replication data, and concordant direction of effect between discovery and replication.
We also undertook a one-stage design to reduce type II error from the two-stage analysis. We used P < 5 × 10 −9 as threshold from the discovery meta-analysis-that is, an order of magnitude more stringent than genome-wide significance 21 -and required an internal replication P < 0.01 in each of the UKB and ICBP GWAS analyses, with concordant direction of effect, to minimize false positive findings.
We carried out conditional analyses using GCTA, a tool for genome-wide complex trait analysis 22 . We then explored putative functions of blood pressure-associated signals using a range of in silico resources and evaluated co-occurrence of blood pressureassociated loci with lifestyle exposures and other complex traits and diseases. Finally, we developed a genetic risk score (GRS) and assessed impact of blood pressure-associated variants on blood pressure, risk of hypertension and other cardiovascular diseases and in other ethnicities.
Results
We present a total of 535 novel loci ( Our two-stage design uniquely identified 121 variants, while 204 also met the one-stage criteria (Fig. 3a) ; many loci would not have been detected by either the one-or two-stage designs alone (Fig. 3a) . For SBP, the distributions of effect sizes are similar for the one-stage (median = 0.219 mm Hg per allele; inter-quartile range (IQR) = 0.202-0.278) and two-stage loci (median = 0.224; IQR = 0.195-0.267) (P = 0.447) ( Supplementary Fig. 2 ). Of the 210 loci found only in the one-stage analysis, 186 were also genomewide significant (P < 5 × 10 −8
) in the combined meta-analysis, with all variants except 1 having concordant direction of effect between discovery and replication (Supplementary Tables 3a-c); of the remaining 24 SNPs, 10 still had concordant direction of effect.
We find support in our data for all 274 previously published blood pressure loci (Supplementary Figs. 1 and 2 and Supplementary  Table 4 ); > 95% of the previously reported SNPs covered within our data are genome-wide significant. Only 6 available SNPs did not reach Bonferroni significance, likely because they were originally A full list of authors and affiliations appear at the end of the paper.
Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits
High blood pressure is a highly heritable and modifiable risk factor for cardiovascular disease. We report the largest genetic association study of blood pressure traits (systolic, diastolic and pulse pressure) to date in over 1 million people of European ancestry. We identify 535 novel blood pressure loci that not only offer new biological insights into blood pressure regulation but also highlight shared genetic architecture between blood pressure and lifestyle exposures. Our findings identify new biological pathways for blood pressure regulation with potential for improved cardiovascular disease prevention in the future.
identified in non-European ancestries (for example, rs6749447, rs10474346, rs11564022) or from a gene-age interaction analysis (rs16833934). In addition, we confirmed a further 92 previously reported but not replicated loci (Supplementary Table 5)   9 ; together with 274 previously reported loci confirmed and 535 novel loci identified here, there are 901 blood pressure-associated loci in total.
Novel genetic loci for blood pressure. Of the 535 independent novel loci, 363 SNPs were associated with one blood pressure trait, 160 with two traits and 12 with all three (Fig. 3b and Supplementary  Fig. 3 ). Using genome-wide complex trait conditional analysis, we further identified 163, genome-wide significant, independent secondary signals with MAF ≥ 1% associated with blood pressure (Supplementary Table 6 ), of which 19 SNPs were in LD (r 2 ≥ 0.1) with previously reported secondary signals. This gives a total of 144 new secondary signals; hence, we now report over 1,000 independent blood pressure signals.
The estimated SNP-wide heritability (h 2 ) of blood pressure traits in our data was 0.213, 0.212 and 0.194 for SBP, DBP and PP, respectively, with a gain in percentage of blood pressure variance explained. For example, for SBP, percentage variance explained increased from 2.8% for the 274 previously published loci to 5.7% for SNPs identified at all 901 loci (Supplementary Table 7 ).
Functional analyses.
Our functional analysis approach is summarized in Supplementary Fig. 4 . First, for each of the 901 loci, we annotated all SNPs (based on LD r 2 ≥ 0.8) to the nearest gene within 5 kb of a SNP, identifying 1,333 genes for novel loci and 1,272 genes for known loci. Then we investigated these loci for tissue enrichment, DNase hypersensitivity site enrichment and pathway. At 66 of the 535 novel loci, we identified 97 non-synonymous SNPs, including 8 predicted to be damaging (Supplementary Table 8) .
We used chromatin interaction Hi-C data from endothelial cells (HUVEC) 23 , neural progenitor cells (NPC), mesenchymal stem cells (HVMSC) and tissue from the aorta (HAEC) and adrenal gland 24 to identify distal associated genes. There were 498 novel loci that contained a potential regulatory SNP, and in 484 of these we identified long-range interactions in at least one of the tissues or cell types. We found several potential long-range target genes that did not overlap with the sentinel SNPs in the LD block. For example, the TGFB2 gene forms a 1.2-Mb regulatory loop with SNPs in the SLC30A10 locus, and the TGFBR1 promoter forms a 100-kb loop with the COL15A1 locus (Supplementary Table 8 ).
Our expression quantitative trait locus (eQTL) analysis identified 60 novel loci with eQTLs in arterial tissue and 20 in adrenal (Supplementary Table 9 ), substantially increasing those identified in our previously published GWAS on ~ 140k UKB individuals 10 . An example is SNP rs31120122, which defines an aortic eQTL affecting expression of the MED8 gene within the SZT2 locus. In combination with Hi-C interaction data in HVMSC, this supports a role for MED8 in blood pressure regulation, possibly mediated through expression of smooth muscle cell differentiation. Hi-C interactions provide supportive evidence for involvement of a further 36 arterial eGenes (genes whose expression is affected by the eQTLs) that are distal to their eQTLs (for example, PPHLN1, ERAP2, FLRT2, ACVR2A, POU4F1).
Using DeepSEA, we found 198 SNPs in 121 novel loci with predicted effects on transcription factor binding or on chromatin marks in tissues relevant for blood pressure biology, such as vascular tissue, smooth muscle and the kidney (Supplementary Table 8) .
We used our genome-wide data at a false discovery rate (FDR) < 1% to robustly assess tissue enrichment of blood pressure loci using DEPICT and identified enrichment across 50 tissues and cells ( Supplementary Fig. 5a and Supplementary Table 10a). Enrichment was greatest for the cardiovascular system, especially blood vessels (P = 1.5 × 10 −11 ) and the heart (P = 2.7 × 10 −5 ). Enrichment was high in adrenal tissue (P = 3.7 × 10 −4 ), and, for the first time to our knowledge, we observed high enrichment in adipose tissues (P = 9.8 × 10 −9 ) corroborated by eQTL enrichment analysis (P < 0.05) ( Supplementary Fig. 6 and Supplementary Table 9 ). Evaluation of enriched mouse knockout phenotype terms also pointed to the importance of vascular morphology (P = 6 × 10 −15 ) and development (P = 2.1 × 10 −18 ) in blood pressure. With addition of our novel blood pressure loci, we identified new findings from both the gene ontology and protein-protein interaction subnetwork enrichments, which highlight the transforming growth factor-β (TGFβ ) (P = 2.3 × 10 −13 ) and related SMAD pathways (P = 7 × 10 −15 ) ( Supplementary Fig. 5b-d and Supplementary Table 10b) .
We used FORGE 25 to investigate the regulatory regions for cell type specificity from DNase I hypersensitivity sites. This showed strongest enrichment (P < 0.001) in the vasculature and highly vascularized tissues, as reported in previous blood pressure genetic studies 10 ( Supplementary Fig. 7 ).
Potential therapeutic targets. Ingenuity pathway analysis and upstream regulator assessment showed enrichment of canonical pathways implicated in cardiovascular disease, including pathways targeted by antihypertensive drugs (for example, nitric oxide signaling), and also suggested some potential new targets, such as relaxin signaling. Notably, upstream regulator analysis identified several blood pressure therapeutic targets, such as angiotensinogen, calcium channels, progesterone, natriuretic peptide receptor, angiotensin converting enzyme, angiotensin receptors and endothelin receptors ( Supplementary Fig. 8 ). −9 in the discovery meta-analysis (n = 757,601), P < 0.01 in UKB (n = 458,577), P < 0.01 in ICBP (n = 299,024) and concordant direction of effect between UKB and ICBP). The P-values for the discovery and the ICBP meta-analyses were calculated using inverse-variance fixedeffects meta-analysis. The P-values in UKB were derived from linear mixed modeling using the software package BOLT-LMM 17 . Of the 325 novel replicated loci from the two-stage analysis (genome-wide significance in the combined meta-analysis, P < 0.01 in the replication meta-analysis and concordant direction of effect), 204 loci would also have met the one-stage criteria, whereas 121 were identified only by the two-stage analysis. b, Overlap of associations across blood pressure traits. For all 535 novel loci, we show the number of loci associated with each blood pressure trait. We present the two-stage loci first, followed by the one-stage loci.
We developed a cumulative tally of functional evidence at each variant to assist in variant or gene prioritization at each locus and present a summary of the vascularly expressed genes contained within the 535 novel loci, including a review of their potential druggability ( Supplementary Fig. 9 ). The overlap between blood pressure-associated genes and those associated with antihypertensive drug targets further demonstrates new genetic support for known drug mechanisms. For example, we report five novel blood pressure associations with targets of five antihypertensive drug classes (Supplementary Table 11 ), including the PKD2L1, SLC12A2, CACNA1C, CACNB4 and CA7 loci, targeted by potassium-sparing diuretics (amiloride), loop diuretics (bumetanide and furosemide), dihydropyridine, calcium channel blockers, non-dihydropyridines and thiazide-like diuretics (chlortalidone), respectively. Notably, in all but the last case, functional variants in these genes are the best candidates in each locus.
Concordance of blood pressure variants and lifestyle exposures.
We examined association of sentinel SNPs at the 901 blood pressure loci with blood pressure-associated lifestyle traits 14 in UKB using either the Stanford Global Biobank Engine (n = 327,302) or Gene Atlas (n = 408,455). With corrected P < 1 × 10
, we found genetic associations of blood pressure variants with daily fruit intake, urinary sodium and creatinine concentration, body mass index (BMI), weight, waist circumference, and intakes of water, caffeine and tea (P = 1.0 × 10
). Specifically, SNP rs13107325 in SLC39A8 is a novel locus for frequency of drinking alcohol (P = 3.5 × 10 ) and waist circumference (P = 4.7 × 10 −11
) (Supplementary Table 12 ). We used unsupervised hierarchical clustering for the 36 blood pressure loci that showed at least one association at P < 1 × 10 −6 with the lifestyle-related traits in UKB (Fig. 4) . The heat map summarizes the locus-specific associations across traits and highlights heterogeneous effects with anthropometric traits across the loci examined. For example, it shows clusters of associations between blood pressure-raising alleles and either increased or decreased adult height and weight. We note that some observed cross-trait associations are in opposite directions to those expected epidemiologically.
Association lookups with other traits and diseases. We further evaluated cross-trait and disease associations using GWAS Catalog . The GWAS Catalog and PhenoScanner search of published GWAS showed that 77 of our 535 novel loci (using sentinel SNPs or proxies with r 2 ≥ 0.8) are also significantly associated with other traits and diseases ( Fig. 5 and Supplementary Table 13 ). We identified APOE as a highly cross-related blood pressure locus showing associations with lipid levels, cardiovascular-related outcomes and Alzheimer's disease, highlighting a common link between cardiovascular risk and cognitive decline (Fig. 5 ). Other loci overlap with anthropometric traits, including BMI, birth weight and height (Fig. 5) , and with DisGeNET terms related to lipid measurements, cardiovascular outcomes and obesity (Fig. 6) .
We did lookups of our sentinel SNPs in 1 H NMR lipidomics data on plasma (n = 2,022) and data from the Metabolon platform (n = 1,941) in the Airwave Study 30 , and used PhenoScanner to test SNPs against published significant (P < 5 × 10
) genome-vs. metabolome-wide associations in plasma and urine (Methods). Ten blood pressure SNPs showed association with lipid particle metabolites and a further 31 SNPs (8 also on PhenoScanner) showed association with metabolites on the Metabolon platform, highlighting lipid pathways, amino acids (glycine, serine and glutamine),
Coffee intake For the sentinel SNP at each blood pressure locus (x axis), we calculated the -log 10 (P) × sign(β ) (aligned to blood pressure-raising allele) as retrieved from the Gene Atlas catalog. The P-values in Gene Atlas were calculated applying linear mixed models. Blood pressure loci and traits were clustered according to the Euclidean distance among -log 10 (P) × sign(β ). Red squares indicate direct associations with the trait of interest and blue squares inverse associations. Only SNPs with at least one association at P < 1 × 10 −6 with at least one of the traits examined are annotated in the heat-map. All 901 loci are considered, both known and novel; novel loci are in bold.
tricarboxylic acid cycle intermediates (succinylcarnitine) and drug metabolites (Supplementary Tables 14 and 15 ). These findings suggest a close metabolic coupling of blood pressure regulation with lipid and energy metabolism.
Genetic risk of increased blood pressure, hypertension and cardiovascular disease. A weighted GRS for blood pressure across all 901 loci was associated with a 10.4 mm Hg higher, sex-adjusted mean SBP in UKB comparing the top and bottom quintiles of the GRS distribution (95% CI 10.2 to 10.6 mm Hg, P < 1 × 10 −300 ) and with 12.9 mm Hg difference in SBP (95% CI 12.6 to 13.1 mm Hg, P < 1 × 10 −300 ) comparing the top and bottom deciles (Fig. 7a and  Supplementary Table 16 ). In addition, we observed over threefold sex-adjusted higher risk of hypertension (OR 3.34; 95% CI 3.24 to 3.45; P < 1 × 10 −300 ) between the top and bottom deciles of the GRS in UKB (Fig. 7a) . Sensitivity analyses in the independent Airwave cohort gave similar results (Supplementary Table 17 ). We also found that the GRS was associated with increased, sexadjusted risk of incident stroke, myocardial infarction and all incident cardiovascular outcomes, comparing top and bottom deciles of the GRS distribution, with odds ratios of 1.47 (95% CI 1.35 to 1.59, P = 1.1 × 10 −20 ), 1.50 (95% CI 1.28 to 1.76, P = 8.0 × 10 −7 ) and 1.52 (95% CI 1.26 to 1.82, P = 7.7 × 10 −6 ), respectively (Fig. 7b and  Supplementary Table 16 ).
Extending analyses to other ancestries. We examined associations with blood pressure of both individual SNPs and the GRS among unrelated individuals of African and South Asian descent in UKB for the 901 known and novel loci. Compared to Europeans, 62.4%, 62.5% and 64.8% of the variants among Africans (n = 7,782) and 74.2%, 72.3% and 75% South Asians (n = 10,323) had concordant direction of effect for SBP, DBP and PP, respectively (Supplementary Fig. 10 and Supplementary Table 18 ). Pearson correlation coefficients with effect estimates in Europeans were r 2 = 0.37 and 0.78 for Africans and South Asians, respectively ( Supplementary Fig. 11) . We then applied the European-derived GRS findings to unrelated Africans (n = 6,970) and South Asians (n = 8,827). Blood pressure variants in combination were associated with 6.1 mm Hg (95% CI 4.5 to 7.7; P = 4.9 × 10 
Discussion
Our study of over 1 million people offers an important step forward in understanding the genetic architecture of blood pressure. We identified over 1,000 independent signals at 901 loci for blood pressure traits, and the 535 novel loci more than triples the number of blood pressure loci and doubles the percentage variance explained, illustrating the benefits of large-scale biobanks. By explaining 27% of the estimated heritability for blood pressure, we make major inroads into the missing heritability influencing blood pressure in the population 31 .
The novel loci open the vista of entirely new biology and highlight gene regions in systems not previously implicated in blood pressure regulation. This is particularly timely as global prevalence of people with SBP over 110-115 mm Hg, above which cardiovascular risk increases in a continuous graded manner, now exceeds 3.5 billion, of whom over 1 billion are within the treatment range 32,33 . Our functional analysis highlights the role of the vasculature and associated pathways in the genetics underpinning blood pressure traits. We show a role for several loci in the TGFβ pathway, including SMAD family genes and the TGFβ gene locus itself. This pathway affects sodium handling in the kidney and ventricular remodeling, while plasma levels of TGFβ have recently been correlated with hypertension ( Fig. 8 ) 34, 35 . The activin A receptor type 1C (ACVR1C) gene mediates the effects of the TGFβ family of signaling molecules. A blood pressure locus contains the bone morphogenetic protein 2 (BMP2) gene in the TGFβ pathway, which prevents growth suppression in pulmonary arterial smooth muscle cells and is associated with pulmonary hypertension 36 . Another blood pressure locus includes the Kruppel-like family 14 (KLF14) gene of transcription ≥ 0.8) with genome-wide significant associations. HR, heart rate; ECG, electrocardiographic traits; CAD, coronary artery disease; CHD, coronary heart disease; MI, myocardial infarction; T2D, type 2 diabetes.
factors, which is induced by low levels of TGFβ receptor II gene expression and which has also been associated with type 2 diabetes, hypercholesterolemia and atherosclerosis 37 . Our analysis shows enrichment of blood pressure gene expression in the adrenal tissue. Autonomous aldosterone production by the adrenal glands is thought to be responsible for 5-10% of all hypertension, rising to ~ 20% amongst people with resistant hypertension 38 . Some of our novel loci are linked functionally to aldosterone secretion 39, 40 . For example, the CTNNB1 locus encodes β -catenin, the central molecule in the canonical Wnt signaling system, required for normal adrenocortical development 41, 42 . Somatic adrenal mutations of this gene that prevent serine/threonine phosphorylation lead to hypertension through generation of aldosterone-producing adenomas 43,44 . Our novel loci also include genes involved in vascular remodeling, such as vascular endothelial growth factor A (VEGFA), the product of which induces proliferation, migration of vascular endothelial cells and stimulates angiogenesis. Disruption of this gene in mice resulted in abnormal embryonic blood vessel formation, while allelic variants of this gene have been associated with microvascular complications of diabetes, atherosclerosis and the antihypertensive response to enalapril 45 . We previously reported a fibroblast growth factor (FGF5) gene locus in association with blood pressure 10 . Here, we additionally identify a new blood pressure locus encoding FGF9, which is linked to enhanced angiogenesis and vascular smooth muscle cell differentiation by regulating VEGFA expression.
Several of our novel loci contain lipid-related genes, consistent with the observed strong associations among multiple cardio-metabolic traits. For example, the apolipoprotein E gene (APOE) encodes the major apoprotein of the chylomicron. Recently, APOE serum levels have been correlated with SBP in population-based studies and in murine knockout models; disruption of this gene led to atherosclerosis and hypertension 46, 47 . A second novel blood pressure locus contains the low-density lipoprotein receptor-related protein 4 (LRP4) gene, which may be a target for APOE and is strongly expressed in the heart in mice and humans. In addition, we identified a novel locus including the apolipoprotein L domain containing 1 gene (APOLD1) that is highly expressed in the endothelium of developing tissues (particularly heart) during angiogenesis.
Many of our novel blood pressure loci encode proteins that may modulate vascular tone or signaling. For example, the locus containing urotensin-2 receptor (UTS2R) gene encodes a class A rhodopsin family G-protein coupled-receptor that, upon activation by the neuropeptide urotensin II, produces profound vasoconstriction. One novel locus for SBP contains the relaxin gene, encoding a G-protein coupled receptor, with roles in vasorelaxation and cardiac function; it signals by phosphatidylinositol 3-kinase (PI3K) 48, 49 , an enzyme that inhibits vascular smooth muscle cell proliferation and neo-intimal formation 50 . We identify the PI3K gene here as a novel blood pressure locus. We also identify the novel RAMP2 locus, which encodes an adrenomedullin receptor 51 ; we previously identified the adrenomedullin (ADM) gene as a blood pressure locus 12 .
Adrenomedullin is known to exert differential effects on blood pressure in the brain (vasopressor) and the vasculature (vasodilator). In addition, a locus containing Rho guanine nucleotide exchange factor 25 (ARHGEF25) gene generates a factor that interacts with Rho GTPases involved in contraction of vascular smooth muscle and regulation of responses to angiotensin II 52 . We evaluated the 901 blood pressure loci for extant or potentially druggable targets. Loci encoding MARK3, PDGFC, TRHR, ADORA1, GABRA2, VEGFA and PDE3A are within systems with existing drugs not currently linked to a known antihypertensive mechanism; they may offer repurposing opportunities, for example, detection of SLC5A1 as the strongest repurposing candidate in a new blood pressure locus targeted by the type 2 diabetes drug canagliflozin. This is important as between 8-12% of patients with hypertension exhibit resistance or intolerance to current therapies and repositioning of a therapy with a known safety profile may reduce development costs.
This study strengthens our previously reported GRS analysis indicating that all blood pressure elevating alleles combined could increase SBP by 10 mm Hg or more across quintiles or deciles of the population distribution, substantially increasing risk of cardiovascular events 10 . We previously suggested that genotyping blood pressure elevating variants in the young could lead to targeted lifestyle intervention in early life that might attenuate the blood pressure rise at older ages 10 . We identified several blood pressure-associated loci that are also associated with lifestyle traits, suggesting shared genetic architecture between blood pressure and lifestyle exposures 53 . We adjusted our blood pressure GWAS analyses for BMI to control for possible confounding effects, though we acknowledge the potential for collider bias 54 . Nonetheless, our findings of possible genetic overlap between loci associated with blood pressure and lifestyle exposures could support renewed focus on altering specific lifestyle measures known to affect blood pressure 55 . Despite smaller sample sizes, we observed high concordance with direction of effects on blood pressure traits of blood pressure variants in Africans (> 62%) and South Asians (> 72%). The GRS analyses show that, in combination, blood pressure variants identified in European analyses are associated with blood pressure in non-European ancestries, though effect sizes were 30-40% smaller.
Our use of a two-and one-stage GWAS design illustrates the value of this approach to minimize the effects of stochastic variation and heterogeneity. The one-stage approach included signals that had independent and concordant support (P < 0.01) from both UKB and ICBP, reducing the impact of winners' curse on our findings. Indeed, all but two of the 210 SNPs discovered in the one-stage analysis reach P < 5 × 10 −6 in either UKB or ICBP. To further minimize the risk of reporting false positive loci within our one-stage design, we set a stringent overall discovery meta-analysis P-value threshold of P < 5 × 10
, an order of magnitude smaller than a genome-wide significance P-value, in line with thresholds recommended for whole genome sequencing 22 . We found high concordance in direction of effects between discovery data in the one-stage approach and the replication resources, with similar distributions of effect sizes for the two approaches. We note that 24 of the one-stage SNPs that reached P < 5 × 10 −9 in discovery failed to reach genomewide significance (P < 5 × 10 −8
) in the combined meta-analysis of discovery and replication resources, and hence may still require further validation in future, larger studies.
The new discoveries reported here more than triple the number of loci for blood pressure to a total of 901 and represent a substantial advance in understanding the genetic architecture of blood pressure. The identification of many novel genes across the genome could partly support an omnigenic model for complex traits, where genome-wide association of multiple interconnected pathways is observed. However, our strong tissue enrichment shows particular relevance to the biology of blood pressure and cardiovascular disease 56 , suggesting trait-specificity, which could argue against an omnigenic model. Our confirmation of the impact of these variants on blood pressure level and cardiovascular events, coupled with identification of shared risk variants for blood pressure and adverse lifestyle, could contribute to an early life precision medicine strategy for cardiovascular disease prevention.
URLs. FORGE, http://browser.1000genomes.org/Homo_sapiens/ UserData/Forge?db = core; Fantom5 data, http://fantom.gsc.riken. jp/5/; ENCODE DNase I data, http://hgdownload.cse.ucsc.edu/ goldenPath/hg19/encodeDCC/wgEncodeAwgDnaseMasterSites/ (wgEncodeAwgDnaseMasterSites; accessed using that our analysis was completed, that have been identified and validated as the sentinel SNP in primary analyses from previous blood pressure genetic association studies. These 357 published SNPs correspond to 274 distinct loci, according to locus definition of (i) SNPs within ± 500 kb distance of each other and (ii) SNPs in LD, using a threshold of r 2 ≥ 0.1, calculated with PLINK (v2.0). We then augment this list to all SNPs present within our data, which are contained within these 274 published blood pressure loci; i.e., all SNPs that are located ± 500 kb from each of the 357 published SNPs and/or in LD with any of the 357 previously validated SNPs (r 2 ≥ 0.1).
Identification of novel signals using two-stage and one-stage study designs.
To identify novel signals of association with blood pressure, two complementary study designs (which we term here "two-stage design" and "one-stage design") were implemented in order to maximize the available data and minimize reporting of false positive associations.
Overview of two-stage design. All of the following criteria had to be satisfied for a signal to be reported as a novel signal of association with blood pressure using our two-stage design:
1. The sentinel SNP shows significance (P < 1 × 10
) in the discovery metaanalysis of UKB and ICBP, with concordant direction of effect between UKB and ICBP. 2. The sentinel SNP is genome-wide significant (P < 5 × 10 −8
) in the combined meta-analysis of discovery and replication (MVP and EGCUT) (replication, described below).
3. The sentinel SNP shows support (P < 0.01) in the replication meta-analysis of MVP and EGCUT alone (Supplementary Note 1). 4. The sentinel SNP has concordant direction of effect between the discovery and the replication meta-analyses. 5. The sentinel SNP must not be located within any of the 274 previously reported loci described above.
The primary replicated trait was then defined as the blood pressure trait with the most significant association from the combined meta-analysis of discovery and replication (in the case where a SNP was replicated for more than one blood pressure trait).
Selection of variants from the discovery meta-analysis.
We considered for followup SNPs in loci non-overlapping with previously reported loci according to both an LD threshold at r 2 of 0.1 and a 1-Mb interval region, as calculated by PLINK 64 . We obtained a list of such SNPs with P < 1 × 10 −6 for any of the three blood pressure traits that also had concordant direction of effect between UKB vs. ICBP (Supplementary Table 21 ). By ranking the SNPs by significance in order of minimum P-value across all blood pressure traits, we performed an iterative algorithm to determine the number of novel signals (Supplementary Note 1) and identify the sentinel (most significant) SNP per locus.
Replication analysis. We considered SNPs with MAF ≥ 1% for independent replication in MVP (max n = 220,520) 14 and in EGCUT Biobank (n = 28,742) 15 (Supplementary Note 1). This provides a total of n = 249,262 independent samples for individuals of European descent available for replication. Additional information on the analyses of the two replication datasets is provided in the Supplementary Note 1 and Supplementary Table 1c. The two datasets were then combined using fixed-effects inverse-variance-weighted meta-analysis, and summary results for all traits were obtained for the replication meta-analysis dataset.
Combined meta-analysis of discovery and replication meta-analyses. The metaanalyses were performed within METAL software 63 using fixed-effects inversevariance-weighted meta-analysis (Supplementary Note 1) . The variants from the discovery GWAS that required proxies for replication are shown in Supplementary  Table 22 . The combined meta-analysis of both the discovery data (n = 757,601) and replication meta-analysis (max n = 249,262) provided a maximum sample size of n = 1,006,863.
Overview of one-stage design. Variants that were looked up but did not replicate according to the two-stage criteria were considered in a one-stage design. All of the following criteria had to be satisfied for a signal to be reported as a novel signal of association with blood pressure using our one-stage criteria:
(MESH) terms. We used the Mouse Genome Informatics (MGI) tool to identify blood pressure and cardiovascular relevant mouse knockout phenotypes for all genes linked to blood pressure in our study. We also used IPA to identify genes that interact with known targets of antihypertensive drugs. Genes were also evaluated for evidence of small molecule druggability or known drugs based on queries of the Drug Gene Interaction database.
Lookups in non-European ancestries.
As a secondary analysis, we looked up all known and novel blood pressure-associated SNPs in Africans (n = 7,782) and South Asians (n = 10,322) from UKB using BOLT-LMM analysis for each blood pressure trait within each ancestry (Supplementary Note 1) .
Effects on other traits and diseases. We queried SNPs against GWAS catalog 26 and PhenoScanner 27 , including genetics and metabolomics databases, to investigate cross-trait effects, extracting all association results with genome-wide significance at P < 5 × 10 −8 for all SNPs in high LD (r 2 ≥ 0.8) with the 535 sentinel novel SNPs, to highlight the loci with strongest evidence of association with other traits. We further evaluated these effects using DisGeNET 28, 29 . At the gene level, we carried out over-representation enrichment analysis with WebGestalt 67 on the nearest genes to all blood pressure loci. Moreover, we tested sentinel SNPs at all published and novel (n = 901) loci for association with lifestyle-related data including food, water and alcohol intake; anthropomorphic traits; and urinary sodium, potassium and creatinine excretion using the recently developed Stanford Global Biobank Engine and the Gene Atlas 68 . Both are search engines for GWAS findings for multiple phenotypes in UKB. We deemed a locus significant at a Bonferronicorrected threshold of P < 1 × 10
Genetic risk scores and percentage of variance explained. We calculated a weighted genetic risk score (GRS) (Supplementary Table 24 ) to provide an estimate of the combined effect of the blood pressure-raising variants on blood pressure and risk of hypertension and applied this to the UKB data (Supplementary Note 1). Our analysis included 423,713 unrelated individuals of European ancestry, of whom 392,092 individuals were free of cardiovascular events at baseline.
We assessed the association of the continuous GRS variable on blood pressure and with the risk of hypertension, with and without adjustment for sex. We then compared blood pressure levels and risk of hypertension, respectively, for individuals in the top vs. bottom quintiles of the GRS distribution. Similar analyses were performed for the top vs. bottom deciles of the GRS distribution. All analyses were restricted to the 392,092 unrelated individuals of European ancestry from UKB. As a sensitivity analysis to assess for evidence of bias in the UKB results, we also carried out similar analyses in Airwave, an independent cohort of n = 14,004 unrelated participants of European descent 30 (Supplementary Note 1). We calculated the association of the GRS with cardiovascular disease in unrelated participants in UKB data on the basis of self-reported medical history and linkage to hospitalization and mortality data (Supplementary Table 25 ). We use logistic regression with binary outcome variables for composite incident cardiovascular disease (Supplementary Note 1), incident myocardial infarction and incident stroke (using the algorithmic UKB definitions) and GRS as explanatory variable (with and without sex adjustment).
We also assessed the association of this GRS with blood pressure in unrelated Africans (n = 6,970) and South Asians (n = 8,827) from the UKB to see whether blood pressure-associated SNPs identified from GWAS predominantly in Europeans are also associated with blood pressure in populations of nonEuropean ancestry.
We calculated the percentage of variance in blood pressure explained by genetic variants using the independent Airwave cohort (n = 14,004) (Supplementary Note 1). We considered three different levels of the GRS: (i) all pairwise-independent, LD-filtered (r 2 < 0.1) published SNPs within the known loci; (ii) all known SNPs and sentinel SNPs at novel loci; and (iii) all independent signals at all 901 known and novel loci including the 163 secondary SNPs.
Ethics statement. The UKB study has approval from the North West Multi-Centre Research Ethics Committee. Any participants from UKB who withdrew consent have been removed from our analysis. Each cohort within the ICBP meta-analysis, as well as our independent replication cohorts of MVP and EGCUT, had ethical approval locally. More information on the participating cohorts is available in the Supplementary Note 2.
Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Data availability
The genetic and phenotypic UKB data are available upon application to the UK Biobank (https://www.ukbiobank.ac.uk). ICBP summary data can be accessed through request to the ICBP steering committee. Contact the corresponding authors to apply for access to the data. The UKB + ICBP summary GWAS discovery data can be accessed by request to the corresponding authors and will be available via LDHub (http://ldsc.broadinstitute.org/ldhub/). All replication data generated during this study are included in the published article. For example, association and to minimize false positive findings. The threshold of P < 5 × 10 −9 has been proposed as a more conservative statistical significance threshold, for example, for whole-genome sequencing-based studies 21 . Selection of variants from the meta-analysis of UKB and ICBP was performed as described above for the two-stage design.
Conditional analysis. We performed conditional analyses using the GWAS discovery meta-analysis data in order to identify any independent secondary signals in addition to the sentinel SNPs at the 901 loci. We used two different methodological approaches, each using the genome-wide complex traits analysis (GCTA) software 22 : (i) full genome-wide conditional analysis with joint multivariate analysis and stepwise model selection across all three blood pressure traits, and (ii) locus-specific conditional analysis for the primary blood pressure trait conditioning on the sentinel SNPs within each locus (Supplementary Note 1) . For robustness, secondary signals are only reported if obtained from both approaches. All secondary signals with MAF ≥ 1% were selected at genome-wide significance level and confirmed to be pairwise-LD-independent (r 2 < 0.1), as well as not being in LD with any of the published or sentinel SNPs at any of the 901 blood pressure-associated loci (r 2 < 0.1). In all cases, the UKB data was used as the reference genetic data for LD calculation, restricted to individuals of European ancestry only.
Variant-level functional analyses. We used an integrative bioinformatics approach to collate functional annotation at both the variant level (for each sentinel SNP within all blood pressure loci) and the gene level (using SNPs in LD r 2 ≥ 0.8 with the sentinel SNPs). At the variant level, we use Variant Effect Predictor (VEP) to obtain comprehensive characterization of variants, including consequence (for example, downstream or noncoding transcript exon), information on nearest genomic features and, where applicable, amino acid substitution functional impact, based on SIFT and PolyPhen. The biomaRt R package is used to further annotate the nearest genes.
We evaluated all SNPs in LD (r 2 ≥ 0.8) with our novel sentinel SNPs for evidence of mediation of expression quantitative trait loci (eQTL) in all 44 tissues using the Genotype-Tissue Expression (GTEx) database, to highlight specific tissue types that show eQTLs for a larger than expected proportion of novel loci. We further sought to identify novel loci with the strongest evidence of eQTL associations in arterial tissue in particular. A locus is annotated with a given eGene only if the most significant eQTL SNP for the given eGene is in high LD (r 2 ≥ 0.8) with the sentinel SNP, suggesting that the eQTL signal colocalizes with the sentinel SNP.
We annotated nearest genes, eGenes (genes whose expression is affected by eQTLs) and Hi-C interactors with HUVEC, HVMSC and HAEC expression from the Fantom5 project. Genes that had higher than median expression levels in the given cell types were indicated as expressed.
To identify SNPs in the novel loci that have a noncoding functional effect (influence binding of transcription factors or RNA polymerase, or influence DNase hypersensitivity sites or histone modifications), we used DeepSEA, a deep learning algorithm, which learned the binding and modification patterns of ~ 900 cellfactor combinations 65 . A change of > 0.1 in the binding score predicted by DeepSEA for the reference and alternative alleles was used as cut-off to find alleles with noncoding functional effect (Supplementary Note 1).
We identified potential target genes of regulatory SNPs using long-range chromatin interaction (Hi-C) data from HUVECs 23 , aorta, adrenal glands, neural progenitors and mesenchymal stem cells, which are tissues and cell types that are considered relevant for regulating blood pressure 24 . We find the most significant promoter interactions for all potential regulatory SNPs (RegulomeDB score ≤ 5) in LD (r 2 ≥ 0.8) with our novel sentinel SNPs and published SNPs, and choose the interactors with the SNPs of highest regulatory potential to annotate the loci.
We then performed overall enrichment testing across all loci. First, we used DEPICT 66 (Data-driven Expression Prioritized Integration for Complex Traits) to identify tissues and cells that are highly expressed at genes within the blood pressure loci (Supplementary Note 1) . Second, we used DEPICT to test for enrichment in gene sets associated with biological annotations (manually curated and molecular pathways, phenotype data from mouse knockout studies) (Supplementary Note 1). We report significant enrichments with a false discovery rate < 0.01. The variants tested were (i) the 357 published blood pressureassociated SNPs at the time of analysis and (ii) a set including all (published and novel) variants (with novel SNPs filtered by highest significance, P < 1 × 10
−12
). Furthermore, to investigate cell type specific enrichment within DNase I sites, we used FORGE, which tests for enrichment of SNPs within DNase I sites in 123 cell types from the Epigenomics Roadmap Project and ENCODE 25 (Supplementary Note 1). Two analyses were compared (i) using published SNPs only and (ii) using sentinel SNPs at all 901 loci, in order to evaluate the overall tissue specific enrichment of blood pressure-associated variants. 
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
For the Primary GWAS analysis, BOLT-LMM software v2.3 was used for running an association analysis using linear mixed modelling; then METAL software was used for all meta-analyses with a fixed effects inverse variance weighted meta-analysis approach. We used R software for any general statistical analyses, for secondary analyses (e.g. variance explained analyses, risk score analyses) and for producing plots in the figures. We used PLINK software for LD calculations of variants. For the bioinformatics analyses, specific software was used for each different analysis. Each method and the software used is described in the Online Methods, the Supplementary Methods and also summarised in Supplementary Figure 3 . For example, the Variant Effect Predictor (VEP) tool is used for variant annotation; DEPICT software is used for enrichment testing, etc.
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
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